Claims for Patent: 5,763,184

Summary for Patent: 5,763,184

Title:	Nucleotide sequence variation in the ABO glycosyltransferase gene
Abstract:	Methods and reagents for determining an individual\'s genotype at the ABO locus with respect to newly discovered polymorphisms, which facilitates typing tissue for determinign individual identity and has application in the field of forensic science.
Inventor(s):	Reynolds; Rebecca Lynne (Alameda, CA), Zangenberg; Gabriele Annemarie (Alameda, CA)
Assignee:	Roche Molecular Systems, Inc. (Branchburg, NJ)
Application Number:	08/763,502
Patent Claims:	1. An isolated oligonucleotide which consists of a subsequence of the intron sequence that is nucleotides 1 to 58 of SEQ ID NO: 1 and which comprises a nucleotide sequence at least about 10 nucleotides in length, wherein said nucleotide sequence is contained in the region consisting of positions 22-58 of SEQ ID NO: 1. 2. A DNA vector comprising said oligonucleotide of claim 1. 3. An isolated oligonucleotide about 15 to about 35 nucleotides in length exactly or substantially complementary to either strand of SEQ ID NO: 1 in a region which encompasses a polymorphic site selected from the polymorphic sites at nucleotide positions 29, 32, and 33, and wherein said oligonucleotide is exactly complementary to SEQ ID NO: 1 at said polymorphic site. 4. An isolated oligonucleotide of claim 3, wherein said region is about 15 to about 35 nucleotides in length. 5. An isolated oligonucleotide of claim 3 selected from the group consisting of GZ26 (SEQ ID NO: 4), GZ27 (SEQ ID NO: 5), P1 (SEQ ID NO: 10), P2 (SEQ ID NO: 11), and the exact complements thereof. 6. A kit for determining the genotype of an individual at the ABO glycosyltransferase locus comprising an oligonucleotide of claim 3. 7. A kit for determining the genotype of an individual at the ABO glycosyltransferase locus comprising an oligonucleotide of claim 4. 8. A kit for determining the genotype of an individual at the ABO glycosyltransferase locus comprising an oligonucleotide of claim 5. 9. A method for detecting the presence of a variant sequence of the ABO glycosyltranferase gene in a sample containing human nucleic acids comprising: (a) mixing said nucleic acid with an oligonucleotide about 15 to about 35 nucleotides in length exactly or substantially complementary to either strand of SEQ ID NO: 1 in a region which encompasses a polymorphic site selected from the polymorphic sites at nucleotide positions 29, 32, and 33, wherein said oligonucleotide is exactly complementary to said variant sequence at said polymorphic site, under conditions wherein said oligonucleotide binds to said nucleic acid to form a stable hybrid duplex only if said nucleic acid contains said variant sequence; and (b) detecting the presence of any hybrids formed between said oligonucleotide and said nucleic acid, which indicates the presence of said variant sequence. 10. A method of claim 9, wherein, wherein said region is about 15 to about 35 nucleotides in length. 11. A method of claim 9, wherein said oligonucleotide is selected from the group consisting of GZ26 (SEQ ID NO: 4), GZ27 (SEQ ID NO: 5), P1 (SEQ ID NO: 10), P2 (SEQ ID NO: 11), and the exact complements thereof. 12. A method of claim 9, wherein said nucleic acid is amplified prior to step (a). 13. A method of claim 9, wherein said detecting in step (b) comprises carrying out a amplification reaction, using said oligonucleotide as an amplification primer, under conditions under which amplification occurs only if said oligonucleotide forms a stable hybrid duplex with said nucleic acid.

Details for Patent 5,763,184

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26